Tarsus Pharmaceuticals, Inc.
TARS· Nasdaq
Released Aug 4, 2021, after the close
10-Q filed Aug 5, 2021, 36 days after period end · 0001819790-21-000027
| Metric | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|
| Revenue | $22.02M | $0.00 | — |
| Net Income | $6.35M | -$3.25M | -$831.00K |
| EPS Diluted | $0.29 | -$1.23 | — |
Tarsus Pharmaceuticals, Inc. · CIK 1819790 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.